In Brief: Boston Scientific
This article was originally published in The Gray Sheet
Boston Scientific: Names Philip Le Goff, PhD, group president, Vascular Businesses (Meadox, Medi-tech and Target Therapeutics). Le Goff formerly served as head of strategy and public affairs at Novartis Pharma AG as a member of its global executive committee. Boston Scientific also names Michel Darnaud president of Boston Scientific Europe. Darnaud formerly served as president-Europe for Baxter International's Cardiovascular Group. Delays in executing Boston Scientific's European business strategy contributed to lower-than-expected third quarter results, the company states ("The Gray Sheet" Sept. 15, I&W-10)...
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.